RE-021 (Sparsentan) + Irbesartan

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Focal Segmental Glomerulosclerosis

Conditions

Focal Segmental Glomerulosclerosis

Trial Timeline

Mar 1, 2014 → Mar 25, 2024

NCT ID

NCT01613118

About RE-021 (Sparsentan) + Irbesartan

RE-021 (Sparsentan) + Irbesartan is a phase 2 stage product being developed by Travere Therapeutics for Focal Segmental Glomerulosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01613118. Target conditions include Focal Segmental Glomerulosclerosis.

What happened to similar drugs?

4 of 10 similar drugs in Focal Segmental Glomerulosclerosis were approved

Approved (4) Terminated (1) Active (6)

✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved

✅DapagliflozinAstraZenecaApproved

✅Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved

✅Levetiracetam + Carbamazepine + LamotrigineUCBApproved

🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3

🔄Gadoxetic Acid Disodium (Primovist, BAY86-4873)BayerPhase 3

🔄XEN1101 + PlaceboXenon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01613118	Phase 2	Completed	Mar 1, 2014	Mar 25, 2024	Focal Segmental Glomerulosclerosis

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis

See all competitors

Product	Company	Stage	Hype Score
OnabotulinumtoxinA 145 UNT [Botox]	AbbVie	Approved	35
Dapagliflozin	AstraZeneca	Approved	43
Enfuvirtide + Tenofovir-Emtricitabine	Roche	Phase 2	35
CCX140-B	Amgen	Phase 2	27
PF-06730512	Pfizer	Phase 2	27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide	Pfizer	Approved	43
VX-147	Vertex Pharmaceuticals	Phase 2	35
VX-147	Vertex Pharmaceuticals	Phase 1	29
IXP	Vertex Pharmaceuticals	Phase 1	29
fresolimumab + fresolimumab + Placebo	Sanofi	Phase 2	35
GC1008 + GC1008 + GC1008 + GC1008	Sanofi	Phase 1	29
frexalimab + brivekimig + rilzabrutinib + placebo	Sanofi	Phase 2	42
Vivaglobin	CSL	Phase 2	35
UCB0942	UCB	Phase 2	27
Levetiracetam + Carbamazepine + Lamotrigine	UCB	Approved	43
Brivaracetam + Brivaracetam	UCB	Phase 2	35
Lacosamide	UCB	Phase 2	27
UCB0942 + UCB0942 + Placebo	UCB	Phase 2	35
Lacosamide	UCB	Pre-clinical	26
ARGX-117	Argenx	Phase 2	36